Business
HeartBeam is a medical technology company developing ambulatory cardiac monitoring and ECG technology intended to synthesize a 12-lead ECG from three-dimensional heart-signal data.
HeartBeam remained pre-revenue, widened its loss, but cash burn was roughly flat and insiders bought.
The read at a glance✓ Audited against SEC data
- Business mix — Cardiac ECG medical technologyNote
- Revenue — No revenue in bundle financialsNote
- Losses — Net loss widened to $21.0MWatch
- Cash — Free cash flow roughly flatNote
- Equity — Equity rose 57.4%OK
- Insiders — 8 purchases / 3 salesOK
- Accounting — No current forensic screen in bundleNote
Leadership changes
From HeartBeam, Inc.'s own filings, the day they're filed.
- Mark Strome · departureeff. 2026-06-18
- Mark Strome Resignation On · departureeff. 2026-06-18
- Robert Eno · Chief Executive Officer · appointmenteff. 2025-05-05
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-24
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about HeartBeam, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.